ROR1
ENSG00000185483
Target class
Unclassified protein
Chromosome
1
Approved drugs
0
Clinical candidates (approved and in development)
1
- Approved drugs
- 0
- ClinGen gene-disease validity
- Limited
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- ROR1
- Gene name
- Receptor tyrosine kinase like orphan receptor 1
- Gene symbol
- ROR1
- Previous gene symbols
- NTRKR1
- Protein name
- Inactive tyrosine-protein kinase transmembrane receptor ROR1 (Neurotrophic tyrosine kinase, receptor-related 1)
- Gene biotype
- Protein coding
- Gene family
- Receptor tyrosine kinases|I-set domain containing|Kringle domain containing
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 34
- Highest tissue expression
- 18.25
- Tissue specificity (Gini)
- 0.573
- Tissue specificity (tau)
- 0.85
- KEGG gene identifiers
- hsa:4919
- Reactome pathways
- R-HSA-5140745
- Protein interaction confidence
- 0.785077
- Protein interaction partners
- 13
- End position
- 64181498
- Start position
- 63774017
- Chromosome
- 1
- Strand
- Forward
- Membrane
- Single-pass type I membrane protein. Cell projection, axon .
Publication evidence
- PubMed 27162350
- Tissue specificity (tau)
- 0.849749
- Expression inequality (Gini)
- 0.573076
Expression in transcripts per million
- Artery - Tibial
- 18.25
- Cells - Cultured fibroblasts
- 14.08
- Artery - Aorta
- 11.28
- Artery - Coronary
- 9.21
- Cervix - Endocervix
- 7.84
Expression in transcripts per million
- Artery - Tibial18.25
- Cells - Cultured fibroblasts14.08
- Artery - Aorta11.28
- Artery - Coronary9.21
- Cervix - Endocervix7.84
- Colon - Sigmoid6.83
- Cervix - Ectocervix6.5
- Nerve - Tibial6.17
- Uterus6.07
- Stomach5.7
- Ovary5.67
- Lung4.96
- Adipose - Visceral (Omentum)3.92
- Fallopian Tube3.89
- Bladder3.82
- Vagina3.34
- Adipose - Subcutaneous3.2
- Skin - Sun Exposed (Lower leg)3.16
- Skin - Not Sun Exposed (Suprapubic)2.85
- Prostate2.83
- Esophagus - Mucosa2.71
- Esophagus - Gastroesophageal Junction2.66
- Colon - Transverse2.53
- Breast - Mammary Tissue2.48
- Pancreas2.25
And 29 more, listed on the interactive page.
- GO:0007169
- GO:0007605
- GO:0008283
- GO:0043123
- GO:0005737
- GO:0005886
- GO:0016020
- GO:0043235
- GO:0004714
- GO:0005515
- GO:0005524
- GO:0015026
- GO:0017147
- GO:0038023
- GO:0042813
Related records
Trials (17)
- A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies
- A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
- A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
- A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
- A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
- A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)
- Cirmtuzumab Consolidation for Treatment of Patients With Detectable CLL on Venetoclax
- Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
- Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer
- Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
- Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia
Drugs (1)
- Cirmtuzumab Inactive tyrosine-protein kinase transmembrane receptor ROR1 inhibitor